Recent FDA Approval: Updates in Dupilumab

Recently, the FDA approved dupilumab as an add-on maintenance treatment for children aged 6 months to 5 years with moderate-to-severe atopic dermatitis (AD). This makes dupilumab the only biologic medicine approved from infancy through into adulthood for people with AD.

In this video, Mercedes Gonzalez, MD, discusses the recent FDA approval for dupilumab to treat infants and young children with atopic dermatitis. Her insights include the current treatment landscape for this population and how dupilumab may change the landscape going forward. Dr Gonzalez is a pediatric dermatologist at the University of Miami School of Medicine. She was a part of the prestigious pediatrics program at the Morgan Stanley Children’s Hospital of New York–Columbia University where she specialized in treating skin disorders.

Transcript

Coming soon